Catalyst Pharmaceuticals, Inc.:
Firdapse approved for Lambert-Eaton Myasthenic Syndrome (LEMS) with 3Q19 net revenues of $30.9M and FY19 guidance of approx $100M. Key Firdapse trial readouts in 1H20: Phase 3 trial for MuSK-MG and SMA Type 3 proof of concept trial.
Phase III, Registration Stage
Central Nervous System, Rare Disease
100MM - 500MM
355 Alhambra Circle
Coral Gables, FL 33134
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by